Prof. Dr. Pere Domingo | Antiretroviral Therapy | Best Researcher Award
Senior Consultant | Hospital de la Santa Creu i Sant Pau | Spain
Prof. Dr. Pere Domingo is an internationally recognized clinician-scientist at the Hospital de la Santa Creu i Sant Pau in Barcelona, Spain, with an extensive research portfolio spanning HIV medicine, viral immunology, infectious diseases, and long-term treatment outcomes in people living with HIV. With 727 scientific publications and more than 21,600 citations from over 17,300 citing documents, he has made sustained and influential contributions to the field, reflected in an h-index of 68. His work integrates clinical trials, epidemiological modeling, translational immunology, and therapeutic optimization to advance understanding of HIV pathogenesis, comorbidities, and treatment simplification strategies. Recent publications include studies on HIV vaccine immunogenicity, cardiovascular risk disparities between HIV-positive individuals and the general population, antiretroviral therapy de-escalation, vaccine responsiveness in immunocompromised groups, immune biomarkers associated with cardiovascular injury, and longitudinal body composition outcomes following regimen switches. His collaborations extend across more than 9,000 co-authors, illustrating his role as a major contributor to large, multicentric, and interdisciplinary research networks in Europe and globally. Dr. Domingo’s work emphasizes improving patient quality of life, reducing treatment toxicity, optimizing therapeutic combinations, and enhancing immune recovery in vulnerable populations, including kidney transplant recipients and those with complex comorbidities. His scholarly output also includes high-impact reviews on HIV-associated lipodystrophy, lymphoproliferative disorders, and historical perspectives on infectious diseases, demonstrating a broad conceptual engagement with both modern and classical dimensions of disease. Through rigorous clinical investigation, leadership in multicenter trials, and sustained contributions to evidence-based HIV management, Dr. Domingo has significantly shaped current approaches to antiretroviral therapy, chronic disease monitoring, and long-term care strategies, reinforcing his standing as a leading figure in contemporary HIV and infectious disease research.
Profiles: Scopus | ORCID | Google Scholar
Featured Publications
1. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., Monforte, A. A., … (2003). Decline in the AIDS and death rates in the EuroSIDA study: An observational study. The Lancet, 362(9377), 22–29. Cited by: 1661
2. Smith, C. J., Ryom, L., Weber, R., Morlat, P., Pradier, C., Reiss, P., Kowalska, J. D., … (2014). Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration. The Lancet, 384(9939), 241–248. Cited by: 1220
3. Knobel, H., Alonso, J., Casado, J. L., Collazos, J., González, J., Ruiz, I., … (2002). Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS, 16(4), 605–613.
Cited by: 729
4. Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., … (2008). Maraviroc for previously treated patients with R5 HIV-1 infection. New England Journal of Medicine, 359(14), 1429–1441. Cited by: 958
5. Worm, S. W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., De Wit, S., … (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the three major drug classes: The D:A:D study. Journal of Infectious Diseases, 201(3), 318–330. Cited by: 878
Dr. Pere Pedrol Domingo’s work advances global HIV research through high-impact clinical trials and translational studies that improve antiretroviral therapy outcomes. His contributions continue to elevate patient care standards and inform evidence-based public health strategies.